Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nalini Prasad

Neurology North Bergen, NJ Medical Doctor

NPI 1881787679 CMS profile 84889

8103 Bergenline Ave, North Bergen, NJ 07047

Open in the dashboard

General payments

$14,465

674 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nalini Prasad of North Bergen, NJ is reported in the CMS Open Payments database as having received $14,465 across 674 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,845 141
2024 General $3,381 164
2023 General $2,551 124
2022 General $2,248 116
2021 General $1,075 58
2020 General $702 39
2019 General $662 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nalini Prasad
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Nalini Prasad were reported at $3,845. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Nalini Prasad Neurology median Middle half National median
2019 $662 $474 $118–$2,177 $163
2020 $702 $367 $82–$2,309 $114
2021 $1,075 $438 $104–$2,547 $132
2022 $2,248 $442 $103–$2,388 $149
2023 $2,551 $464 $119–$2,312 $160
2024 $3,381 $468 $119–$2,323 $164
2025 $3,845 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,763 104 payments
  2. Amneal Pharmaceuticals LLC $1,150 51 payments
  3. Lundbeck LLC $1,054 43 payments
  4. EMD Serono, Inc. $994 16 payments
  5. Lilly USA, LLC $728 32 payments
  6. US WorldMeds, LLC $712 47 payments
  7. Axsome Therapeutics, Inc. $596 12 payments
  8. Otsuka America Pharmaceutical, Inc. $577 22 payments
  9. Teva Pharmaceuticals USA, Inc. $534 31 payments
  10. Pfizer Inc. $516 42 payments
  11. Other $5,842 274 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,300 665 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $90 5 payments
  3. Education $75 4 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,244 73 payments
  2. VYEPTI $949 35 payments
  3. QULIPTA $756 41 payments
  4. REXULTI $564 21 payments
  5. RYTARY $528 27 payments
  6. INGREZZA $474 26 payments
  7. ZAVZPRET $426 36 payments
  8. NURTEC ODT $421 36 payments
  9. CREXONT $371 10 payments
  10. APOKYN $370 33 payments
  11. Other $8,386 397 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 70 drugs

Part D claims

6,878

Median for Neurology: 833

Drug cost

$720,450

Median for Neurology: $202,670

Branded share of claims

18.8%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 29 $174,808
Rexulti Brexpiprazole Brand 60 $91,331
Copaxone Glatiramer Acetate Brand 12 $83,564
Ubrelvy Ubrogepant Brand 44 $48,802
Rytary Carbidopa/Levodopa Brand 62 $38,597
Nurtec Odt Rimegepant Sulfate Brand 20 $25,992
Emgality Pen Galcanezumab-Gnlm Brand 36 $25,972
Aptiom Eslicarbazepine Acetate Brand 21 $25,110
Xcopri Cenobamate Brand 22 $24,285
Namzaric Memantine Hcl/Donepezil Hcl Brand 24 $19,960

The 10 drugs with the highest cost, of 70 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$107,640

Medicare's payments for the services billed

Medicare patients

280

Average age 76

Services billed

957

202 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 59%
Alzheimer's or dementia 33%
Ischemic heart disease 30%
Depression 30%
Osteoporosis 29%
Chronic kidney disease 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYEPTI
$409 — —
REXULTI
$314 60 —
UBRELVY
$275 44 —
INGREZZA
$266 — —
Apokyn
$213 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

674 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record